Lung Cancer

Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC.

Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program.

Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer.

Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients.

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment.

A recently released report indicates that low-dose computed tomography targeted screening for lung cancer confers patient health and public health benefits.

A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials.

In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups.

Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment.

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment.